Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients-Reference-Cited by-同舟云学术

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Published:2020-09-19 Issue:5 Volume:112 Page:640-649
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Takezako Naoki,Kosugi Hiroshi,Matsumoto Morio,Iida Shinsuke,Ishikawa Takayuki,Kondo Yukio,Ando Kiyoshi,Miki Hirokazu,Matsumura Itaru,Sunami Kazutaka,Teshima Takanori,Iwasaki Hiromi,Onishi Yasushi,Kizaki Masahiro,Izutsu Koji,Maruyama Dai,Tobinai Kensei,Ghori Razi,Farooqui Mohammed,Liao Jason,Marinello Patricia,Matsuda Kenji,Koh Yasuhiro,Shimamoto Takashi,Suzuki Kenshi

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02953-3.pdf

Reference35 articles.

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2018.

2. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221–7.

3. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5:e349.

4. Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol. 2019;109:509–38.

5. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28:iv52–iv61.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. 多発性骨髄腫を合併した進行肺癌に対してレナリドミド，デキサメタゾン療法とペムブロリズマブを併用した1例;Haigan;2023-06-20

3. Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma;The Oncologist;2021-03-10